{"id":"placebo-im","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5853147","moleculeType":null,"molecularWeight":"381.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, it contains no active pharmaceutical ingredient and works through the placebo effect—the therapeutic benefit derived from patient expectation and the clinical context of treatment rather than any direct molecular mechanism. Placebo IM was developed by Alexza Pharmaceuticals as a delivery system for rapid-onset medications, though the placebo formulation itself has no intrinsic pharmacological activity.","oneSentence":"Placebo IM is an inert substance administered by intramuscular injection that produces no pharmacological effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:41:56.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT06077760","phase":"PHASE3","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Non-small Cell Lung Cancer","enrollment":868},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT06669208","phase":"PHASE1","title":"Trial of an Inactivated Chikungunya Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2024-11-04","conditions":"Chikungunya Fever, Chikungunya Virus, Chikungunya","enrollment":48},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT04191499","phase":"PHASE2, PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-29","conditions":"Breast Cancer","enrollment":325},{"nctId":"NCT03220724","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-22","conditions":"HIV Infections","enrollment":117},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":"Chikungunya Virus","enrollment":6144},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT07298434","phase":"PHASE3","title":"Study of VYD2311 for the Prevention of COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Invivyd, Inc.","startDate":"2026-01-08","conditions":"COVID-19","enrollment":1770},{"nctId":"NCT06310551","phase":"PHASE1","title":"First Time in Human Study of Long Acting VH4524184 Formulations","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-03-21","conditions":"HIV Infections","enrollment":268},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT06961006","phase":"PHASE2","title":"A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-29","conditions":"Malignant Melanoma","enrollment":160},{"nctId":"NCT07454915","phase":"PHASE2","title":"PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia","status":"NOT_YET_RECRUITING","sponsor":"PapiVax Biotech, Inc.","startDate":"2026-03-01","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16","enrollment":138},{"nctId":"NCT07210463","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)","status":"RECRUITING","sponsor":"Merz Aesthetics GmbH","startDate":"2025-10-01","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT07450638","phase":"NA","title":"Effect of Preoperative Long-Acting Corticosteroids on Pain, Swelling, and Trismus After Impacted Lower Third Molar Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al Salam University","startDate":"2026-01-04","conditions":"Impacted Mandibular Third Molar, Postoperative Pain, Trismus","enrollment":60},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06036602","phase":"PHASE2","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2024-07-15","conditions":"Ebola Sudan Virus Disease","enrollment":125},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT06592794","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-24","conditions":"Acute Gastroenteritis, Norovirus Acute Gastroenteritis","enrollment":37864},{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT06831812","phase":"PHASE1","title":"Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine","status":"COMPLETED","sponsor":"Nuravax, Inc.","startDate":"2024-06-12","conditions":"Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention","enrollment":16},{"nctId":"NCT06694753","phase":"PHASE1","title":"Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-12-15","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT06544616","phase":"PHASE2","title":"A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2024-07-22","conditions":"Preclinical Alzheimer's Disease","enrollment":498},{"nctId":"NCT05348993","phase":"PHASE2","title":"Single or Repeat Dose of G03-52-01 in Adult Subjects","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-06-15","conditions":"Healthy, Botulinum Toxin","enrollment":622},{"nctId":"NCT07175662","phase":"PHASE2","title":"Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL","status":"RECRUITING","sponsor":"Newish Biotech (Wuxi) Co., Ltd.","startDate":"2025-11-11","conditions":"High-grade Squamous Intraepithelial Lesion (HSIL)","enrollment":150},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT04767373","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-07","conditions":"Respiratory Syncytial Virus Infection","enrollment":3632},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT06803342","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-06-26","conditions":"Ebola Sudan Virus Disease","enrollment":200},{"nctId":"NCT06071767","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-01","conditions":"HIV-1-infection","enrollment":36},{"nctId":"NCT02763566","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-12-05","conditions":"Breast Cancer","enrollment":463},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT06634797","phase":"PHASE4","title":"A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-10-08","conditions":"Healthy Volunteers","enrollment":1000},{"nctId":"NCT06639997","phase":"PHASE1","title":"Safety and Tolerability of AZD5148 in Japanese Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-31","conditions":"Clostridioides Difficile Infection","enrollment":16},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT04607408","phase":"PHASE1","title":"Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2020-11-10","conditions":"HIV Infections","enrollment":38},{"nctId":"NCT03284866","phase":"PHASE3","title":"HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2019-07-31","conditions":"AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection","enrollment":536},{"nctId":"NCT04650581","phase":"PHASE3","title":"Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-01-27","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT06015308","phase":"PHASE2","title":"A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-06","conditions":"Dermatitis Atopic","enrollment":224},{"nctId":"NCT06620003","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-04-14","conditions":"Marburg Virus Disease","enrollment":200},{"nctId":"NCT05770895","phase":"PHASE1","title":"Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-04-03","conditions":"Chronic Hepatitis B","enrollment":83},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT06305767","phase":"PHASE1, PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-03-28","conditions":"Bladder Cancer","enrollment":230},{"nctId":"NCT06310291","phase":"EARLY_PHASE1","title":"VTP-1000 in Adults With Celiac Disease","status":"RECRUITING","sponsor":"Barinthus Biotherapeutics","startDate":"2024-08-01","conditions":"Celiac Disease","enrollment":45},{"nctId":"NCT03455725","phase":"NA","title":"CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioCardia, Inc.","startDate":"2021-06-30","conditions":"Refractory Angina, Chronic Myocardial Ischemia","enrollment":343},{"nctId":"NCT06967259","phase":"PHASE1","title":"ENA-001 for Opioid Induced Respiratory Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enalare Therapeutics Inc.","startDate":"2025-05-14","conditions":"Respiratory Depression","enrollment":36},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT07311148","phase":"PHASE2","title":"A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-23","conditions":"Herpes Zoster (HZ), Shingles, VZV","enrollment":840},{"nctId":"NCT06625541","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers","status":"COMPLETED","sponsor":"AnnJi Pharmaceutical Co., Ltd.","startDate":"2024-06-24","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT05182125","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2021-11-25","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT06735248","phase":"PHASE2","title":"A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-04-16","conditions":"Multiple Sclerosis","enrollment":180},{"nctId":"NCT03638999","phase":"EARLY_PHASE1","title":"NSAIDs Stent Study","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-07-31","conditions":"Ureteral Stent Placement, Kidney Stone","enrollment":36},{"nctId":"NCT07295028","phase":"PHASE1","title":"Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults","status":"RECRUITING","sponsor":"Vicebio Australia Proprietary Limited","startDate":"2025-11-17","conditions":"Lower Respiratory Tract Disease, Healthy Participants","enrollment":240},{"nctId":"NCT05317819","phase":"PHASE3","title":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Polaris Group","startDate":"2022-03-14","conditions":"Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07240558","phase":"PHASE3","title":"Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-11-03","conditions":"Influenza (Pandemic), Avian Influenza, Vaccination","enrollment":120},{"nctId":"NCT05575492","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-11-07","conditions":"Cytomegalovirus","enrollment":873},{"nctId":"NCT05085366","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2021-10-26","conditions":"Cytomegalovirus Infection","enrollment":7454},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT06686654","phase":"PHASE1, PHASE2","title":"Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-11","conditions":"Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization","enrollment":1530},{"nctId":"NCT07272434","phase":"PHASE3","title":"Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","status":"RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-10-22","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":25000},{"nctId":"NCT06613789","phase":"PHASE1","title":"Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected","status":"NOT_YET_RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2026-07-13","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT05903183","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age","status":"COMPLETED","sponsor":"Icosavax, Inc.","startDate":"2023-05-15","conditions":"Healthy","enrollment":264},{"nctId":"NCT04899336","phase":"PHASE3","title":"A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-30","conditions":"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","enrollment":17935},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT07226882","phase":"PHASE3","title":"A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-19","conditions":"Lyme Borreliosis","enrollment":200},{"nctId":"NCT05212948","phase":"PHASE3","title":"A Study of S-268019 for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2021-12-25","conditions":"SARS-CoV-2","enrollment":9902},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05743881","phase":"PHASE1","title":"A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-02-15","conditions":"Respiratory Syncytial Virus, Human Metapneumovirus","enrollment":186},{"nctId":"NCT01892722","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT05689645","phase":"PHASE2","title":"F573 for Injection for the Treatment of Liver Injury/Failure","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-03-24","conditions":"Acute Liver Failure, Acute-On-Chronic Liver Failure","enrollment":97},{"nctId":"NCT04060277","phase":"PHASE2","title":"Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-11-27","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT06546709","phase":"PHASE1","title":"DMID 23-0015; Lassa Fever CVD 1000","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wilbur Chen, MD, MS","startDate":"2025-01-13","conditions":"Lassa Fever","enrollment":55},{"nctId":"NCT06205589","phase":"PHASE2","title":"Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB","status":"NOT_YET_RECRUITING","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2026-02-15","conditions":"Tuberculosis, Pulmonary","enrollment":1500},{"nctId":"NCT04908683","phase":"PHASE3","title":"A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-07-21","conditions":"Respiratory Syncytial Viruses, Lower Respiratory Tract Disease","enrollment":25236},{"nctId":"NCT05099965","phase":"PHASE2","title":"Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-02","conditions":"Cytomegalovirus Infections, HIV Infections, Vaccine","enrollment":90},{"nctId":"NCT06469151","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-06-24","conditions":"Healthy Participants","enrollment":84},{"nctId":"NCT07215520","phase":"PHASE2","title":"Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults","status":"RECRUITING","sponsor":"CastleVax Inc.","startDate":"2025-11-03","conditions":"COVID-19","enrollment":200},{"nctId":"NCT07122193","phase":"PHASE3","title":"A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States","status":"RECRUITING","sponsor":"Merz North America, Inc.","startDate":"2025-08-27","conditions":"Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs","enrollment":300},{"nctId":"NCT06810934","phase":"PHASE1, PHASE2","title":"A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses","status":"RECRUITING","sponsor":"Kara Chew","startDate":"2025-10-21","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":80},{"nctId":"NCT02927210","phase":"PHASE1","title":"Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)","status":"COMPLETED","sponsor":"Kimberly Myer","startDate":"2017-02-15","conditions":"Healthy Men, Male Contraception","enrollment":106},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT04938830","phase":"PHASE3","title":"Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-30","conditions":"RSV Infection","enrollment":1003},{"nctId":"NCT02107703","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-07-22","conditions":"Breast Neoplasms","enrollment":669}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saline","Placebo"],"phase":"marketed","status":"active","brandName":"Placebo IM","genericName":"Placebo IM","companyName":"Alexza Pharmaceuticals, Inc.","companyId":"alexza-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}